Trial Profile

A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Jun 2023 Results using individual-level participant data from LEADER , SUSTAIN 6 and PIONEER 6 , comparing cardiovascular (CV) protective effect of liraglutide vs semaglutide in subjects with type 2 diabetes, presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
20 Jun 2022 Results assessing cardiovascular (CV) efficacy of liraglutide and semaglutide in patients with type 2 diabetes (T2D) and peripheral artery disease from LEADER and SUSTAIN-6 studies, published in the Diabetes, Obesity and Metabolism.
14 Dec 2021 Results of pooled analysis from SUSTAIN 6 and LEADER, assessing assessed the effect of once-weekly semaglutide and once daily liraglutide on kidney outcomes in type 2 diabetes, published in the Circulation

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com